About evitria
evitria is a company based in Schlieren (Switzerland) founded in 2010 was acquired by Atlas Antibodies in July 2021. evitria offers products and services including Recombinant Antibodies, Afucosylated Antibodies, Bispecific Antibodies, Fc-silenced Antibodies, and Other Proteins. evitria operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Schlieren, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evitria Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Atlas Antibodies
& 2 more
-
Employee Count
Not available
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of evitria
evitria offers a comprehensive portfolio of products and services, including Recombinant Antibodies, Afucosylated Antibodies, Bispecific Antibodies, Fc-silenced Antibodies, and Other Proteins.
Service for expressing antibodies in CHO cells with fast turnaround.
Antibodies enhanced for increased ADCC activity in therapeutics.
Antibodies targeting multiple antigens for complex applications.
Antibodies designed to reduce effector functions effectively.
Service for producing various secreted proteins as needed.
Funding Insights of evitria
Detailed funding history for evitria
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in evitria
evitria has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Antibodies, SHS Capital and Afinum.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare-focused private equity investments are managed by SHS Capital.
|
Locked | Locked | Locked | |
|
Private equity investments are managed by Afinum for mid-sized companies.
|
Locked | Locked | Locked | |
|
Antibodies and research reagents targeting human proteins are developed.
|
Locked | Locked | Locked |
Investor details for evitria
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by evitria
Investment portfolio details for evitria
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - evitria
Detailed financials for evitria
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evitria Comparisons
Peer comparison for evitria
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of evitria
evitria operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of evitria
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evitria
Complete news archive for evitria
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about evitria
evitria was founded in 2010.
evitria is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Christian Eberle is the current CEO of evitria.
Founded in 2010, evitria operates as a contract research organization based in Schlieren, Switzerland. Focus is placed on transient protein expression using CHO cells, with services extended to recombinant antibodies, afucosylated antibodies, and other proteins. Operations support biotech and pharmaceutical sectors through these specialized expression capabilities, enabling research and development in antibody and protein therapeutics.
evitria's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
evitria offers Recombinant Antibodies, Afucosylated Antibodies, Bispecific Antibodies, Fc-silenced Antibodies, and Other Proteins.
evitria has 3 investors. Key investors include Atlas Antibodies, SHS Capital, and Afinum.